Sirolimus

Generic Name
Sirolimus
Brand Names
Fyarro, Hyftor, Rapamune
Drug Type
Small Molecule
Chemical Formula
C51H79NO13
CAS Number
53123-88-9
Unique Ingredient Identifier
W36ZG6FT64
Background

Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...

Indication

Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...

Associated Conditions
Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
Associated Therapies
-
Clinical Trials
Related News

Methods of T Cell Depletion Trial (MoTD)

First Posted Date
2021-05-17
Last Posted Date
2023-09-28
Lead Sponsor
University of Birmingham
Target Recruit Count
400
Registration Number
NCT04888741
Locations
🇬🇧

Queen Elizabeth Hospital, Birmingham, United Kingdom

🇬🇧

Bristol Haematology and Oncology Centre, Bristol, United Kingdom

🇬🇧

University Hospital of Wales, Cardiff, Wales, United Kingdom

and more 12 locations

Weekly Sirolimus Therapy

Phase 2
Recruiting
Conditions
Venous Malformation
Lymphatic Malformation
Interventions
Drug: Sirolimus
First Posted Date
2021-04-27
Last Posted Date
2024-03-15
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
24
Registration Number
NCT04861064
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

Phase III Trial of Sirolimus in IBM

Phase 3
Recruiting
Conditions
Inclusion Body Myositis
Interventions
Drug: Placebo
Drug: Sirolimus
First Posted Date
2021-03-09
Last Posted Date
2023-04-13
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
140
Registration Number
NCT04789070
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇦🇺

Concord Repatriation Hospital, Sydney, New South Wales, Australia

and more 6 locations

Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.

Phase 2
Completed
Conditions
Kaposiform Hemangioendothelioma
Interventions
Drug: Sirolimus
First Posted Date
2021-03-01
Last Posted Date
2024-05-07
Lead Sponsor
West China Hospital
Target Recruit Count
79
Registration Number
NCT04775173
Locations
🇨🇳

West China Hospital of Sichuan University, Chengdu, Sichuan, China

Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]

Phase 2
Recruiting
Conditions
Aging
Interventions
Drug: rapamycin
First Posted Date
2021-02-08
Last Posted Date
2024-02-23
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
12
Registration Number
NCT04742777
Locations
🇺🇸

The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

🇺🇸

Audie L. Murphy Memorial Veterans Hospital, San Antonio, Texas, United States

Sirolimus Treatment Of Patients With SLE

Phase 2
Not yet recruiting
Conditions
Lupus Erythematosus, Systemic
Interventions
Other: Placebo
Drug: Sirolimus
First Posted Date
2021-02-03
Last Posted Date
2023-06-05
Lead Sponsor
State University of New York - Upstate Medical University
Target Recruit Count
220
Registration Number
NCT04736953

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

First Posted Date
2021-02-03
Last Posted Date
2021-02-03
Lead Sponsor
Peking Union Medical College
Target Recruit Count
270
Registration Number
NCT04736589
Locations
🇨🇳

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Sirolimus for Retinal Astrocytic Hamartoma

Not Applicable
Completed
Conditions
Retinal Astrocytic Hamartoma
Interventions
Drug: Sirolimus
First Posted Date
2021-01-13
Last Posted Date
2024-03-25
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
1
Registration Number
NCT04707209
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

Rapamycin - Effects on Alzheimer's and Cognitive Health

First Posted Date
2020-11-16
Last Posted Date
2024-08-13
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
40
Registration Number
NCT04629495
Locations
🇺🇸

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio, Texas, United States

Sirolimus for Graves' Orbitopathy (GO)

Phase 2
Not yet recruiting
Conditions
Graves Ophthalmopathy
Interventions
Drug: Sirolimus
First Posted Date
2020-10-22
Last Posted Date
2023-03-15
Lead Sponsor
University of Pisa
Target Recruit Count
54
Registration Number
NCT04598815
Locations
🇮🇹

Ospedale Cisanello-Endocrinology II, Pisa, Italy

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy